- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, +4 more
- Locations
-
- Cancer Center at Saint Joseph's Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Clinical trial condition
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Explore clinical trials studying Stage III Bladder Urothelial Carcinoma AJCC v6 and v7. Study availability and eligibility vary by location and protocol.
7 public trials
1 recruiting study
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 trial results
NCT03421652
- Conditions
- Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Locations
-
- Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
- Roswell Park Cancer Institute Buffalo, New York, United States
NCT02178241
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +20 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Los Angeles County-USC Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- Keck Medical Center of USC Pasadena Pasadena, California, United States
Active, Not Recruiting
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT03244384
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Localized Renal Pelvis and Ureter Urothelial Carcinoma, +19 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
Active, Not Recruiting
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
NCT03047213
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +18 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- Keck Medical Center of USC Pasadena Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
Active, Not Recruiting
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
NCT02812420
- Conditions
- Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hydronephrosis, +30 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
NCT00365157
- Conditions
- Advanced Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +9 more
- Locations
-
- Tower Cancer Research Foundation Beverly Hills, California, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- City of Hope Antelope Valley Lancaster, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States